Benzimidazol-2-amines as mIDH1 inhibitors

US10442772B2 · kind B2 · utility

Assignee

• Bayer Pharma Aktiengesellschaft · DE

Inventors

• Hartmut Rehwinkel · Berlin, DE
• Olaf Panknin · Berlin, DE
• Sven Ring · Jena, DE
• Sonja Anlauf · Wuppertal, DE
• Holger Siebeneicher · Berlin, DE
• Duy Nguyen · Berlin, DE
• Wolfgang Schwede · Berlin, DE
• Marcus Bauser · Berlin, DE
• Katja Zimmermann · Mülheim an der Ruhr, DE
• Stefan Kaulfuss · Berlin, DE
• Roland Neuhaus · Berlin, DE
• Paul Matthew Blaney · Harlow, GB

Key dates

• Filing date: Mar 16, 2018
• Grant date: Oct 15, 2019
• Expiry date: Mar 16, 2038

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D401/12
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to benzimidazol-2-amines of general formula (I), in which R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11 and R12 are as defined herein, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of neoplasms, as a sole agent or in combination with other active ingredients.